Related Experiment Video
Updated: May 5, 2026

Early Pathological and Magnetic Resonance Detection of Cerebral Injury Using a Rat Model of Neonatal Hypoxic Ischemic Encephalopathy
Published on: October 28, 2022
White matter injury induced by perinatal exposure to glutaric acid
Silvia Olivera-Bravo1, Eugenia Isasi, Anabel Fernández
1Neurobiología Celular y Molecular, IIBCE, Av. Italia 3318, 11600, Montevideo, Uruguay.
Insights
Glutaric acid (GA) causes lasting myelination failure in the rat striatum, impacting myelin proteins and oligodendrocyte health. This neurotoxin selectively damages white matter, suggesting a progressive mechanism for myelin damage in glutaric acidemia-I.
Area of Science:
- Neuroscience
- Biochemistry
- Neuropathology
Background:
- Glutaric acid (GA) is a neurotoxin accumulating in glutaric acidemia-I (GA-I) patients.
- GA-I is linked to CNS lesions, particularly in basal ganglia and cerebral cortex.
- Oligodendrocyte (OL) and myelination effects of GA are poorly understood.
Purpose of the Study:
- Investigate the impact of GA on oligodendrocytes and myelination in the postnatal brain.
- Determine the specific mechanisms and long-term consequences of GA-induced white matter injury.
Main Methods:
- Intracerebroventricular administration of GA to neonatal rats.
- Assessment of myelination, myelin protein expression (MBP, MAG), and OL pathology.
- Immunohistochemistry (NG2, PDGFRα) and transmission electron microscopy.
Main Results:
- Single GA injection caused long-lasting, selective myelination failure in the striatum.
- Reduced myelinated area (35%) and myelin proteins (MBP 25%, MAG 60%) in the striatum.
- GA induced progressive OL damage, astrocytosis, and neuronal loss without acute pre-OL loss.
Conclusions:
- GA permanently impairs myelin status through a progressive, indirect mechanism.
- White matter injury is restricted to the striatum, highlighting regional vulnerability.
- Findings elucidate a pathogenic pathway for GA-induced demyelination in GA-I.
Abstract:
Glutaric acid (GA) is a neurotoxic metabolite that accumulates in the CNS of patients with glutaric acidemia-I (GA-I), a neurometabolic disease caused by deficient activity of glutaryl-CoA dehydrogenase. Most GA-I patients display characteristic CNS lesions, mainly in the gray and white matter of basal ganglia and cerebral cortex. Neurons and astrocytes are believed to be vulnerable to millimolar concentrations of GA. However, little is known about the effects of GA on oligodendrocytes (OL) and the myelination process in the postnatal brain. Here, we show that a single intracerebroventricular administration of GA to rat neonatal pups induced a selective and long-lasting myelination failure in the striatum but no deleterious effect in the myelination of the corpus callosum. At 45 days post-GA injection, the myelinated area of striatal axonal bundles was decreased by 35 %, and the expression of myelin basic protein and myelin-associated glycoprotein (MAG) reduced by 25 and 60 %, respectively. This was accompanied by long lasting cytopathology features in MAG and CC-1-expressing OLs, which was confirmed by transmission electron microscopy. Remarkably, GA did not induce acute loss of pre-OLs in the striatum as assessed by NG2 or PDGFRα immunohistochemistry, suggesting an indirect and progressive mechanism for OL damage. In accordance, GA-induced white matter injury was restricted to the striatum and associated to GA-induced astrocytosis and neuronal loss. In conclusion, the current evidence indicates a pathogenic mechanism by which GA can permanently affect myelin status.
Related Concept Videos
Secondary Spinal Cord Injury llI: Pathophysiology
Hepatic Encephalopathy
Encephalitis ll: Pathophysiology
Cerebral Edema ll: Pathophysiology

